Arcus Biosciences (RCUS) Liabilities and Shareholders Equity (2017 - 2026)

Arcus Biosciences' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $997.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 16.92% year-over-year to $997.0 million; the TTM figure through Mar 2026 stood at $4.2 billion (down 13.71% YoY), while the FY2025 annual figure was $1.1 billion, down 0.96% from the prior year.
• Liabilities and Shareholders Equity was $997.0 million for Q1 2026 at Arcus Biosciences, down from $1.1 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.5 billion in Q1 2022 to a low of $974.0 million in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $1.2 billion across 5 years, with a median of $1.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity soared 66.07% in 2022, then slipped 25.08% in 2025.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.3 billion in 2022, then declined by 15.77% to $1.1 billion in 2023, then gained by 5.02% to $1.2 billion in 2024, then fell by 0.96% to $1.1 billion in 2025, then dropped by 12.47% to $997.0 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $997.0 million (Q1 2026), $1.1 billion (Q4 2025), and $974.0 million (Q3 2025), per Business Quant data.